Skandinaviska Enskilda Banken AB publ lessened its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 101,374 shares of the biotechnology company’s stock after selling 5,875 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.06% of Iovance Biotherapeutics worth $648,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Envestnet Asset Management Inc. boosted its stake in Iovance Biotherapeutics by 17.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 14,017 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 2,099 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in Iovance Biotherapeutics by 71.8% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,085,121 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 453,337 shares in the last quarter. Raymond James & Associates boosted its stake in Iovance Biotherapeutics by 53.3% in the 1st quarter. Raymond James & Associates now owns 15,386 shares of the biotechnology company’s stock valued at $256,000 after buying an additional 5,350 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Iovance Biotherapeutics by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,772,007 shares of the biotechnology company’s stock valued at $29,504,000 after buying an additional 104,913 shares in the last quarter. Finally, AlphaCrest Capital Management LLC boosted its stake in Iovance Biotherapeutics by 11.7% in the 1st quarter. AlphaCrest Capital Management LLC now owns 17,538 shares of the biotechnology company’s stock valued at $292,000 after buying an additional 1,838 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.
Analyst Ratings Changes
Several analysts recently commented on the company. Truist Financial boosted their price target on Iovance Biotherapeutics from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, January 24th. Piper Sandler upgraded Iovance Biotherapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $11.00 to $14.00 in a research report on Friday, January 27th. StockNews.com upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Oppenheimer cut their price objective on Iovance Biotherapeutics from $25.00 to $15.00 and set an “outperform” rating for the company in a research report on Wednesday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Iovance Biotherapeutics in a research report on Wednesday, March 1st. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.70.
Iovance Biotherapeutics Stock Down 0.4 %
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.34. During the same period in the prior year, the company posted ($0.58) EPS. As a group, equities research analysts anticipate that Iovance Biotherapeutics, Inc. will post -2.82 earnings per share for the current fiscal year.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors.
Further Reading
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- MarketBeat Week in Review – 5/8 – 5/12
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
